American Society of Nephrology Kidney Week 2019

Individuals with chronic kidney disease (CKD) had an increased risk of reaching clinically relevant eGFR* decline thresholds compared with individuals who are at risk** for CKD, with diabetes and albuminuria independently predicting this risk, according to data presented at ASN Kidney Week 2019.

A 3-year sustained reduction of serum uric acid (SUA) with allopurinol was of no benefit to type 1 diabetes (T1D) patients with mild-to-moderate kidney disease, according to the PERL* study presented at the ASN 2019 Meeting.

Excess androgen in women is associated with increases in blood pressure (BP), claims an expert who presented several studies at the recent Kidney Week 2019 of the American Society of Nephrology.

Treatment with the SGLT2* inhibitor dapagliflozin appears to attenuate renal decline in patients with heart failure and reduced ejection fraction (HFrEF), regardless of whether they have CKD, according to a prespecified subanalysis of the landmark DAPA-HF trial presented at ASN Kidney Week 2019.

Combination therapy with empagliflozin plus linagliptin (E+L) reduces glomerular filtration rate (GFR), whereas metformin plus insulin glargine (M+I) confers benefits for both GFR and renal plasma flow (RPF) in type 2 diabetes mellitus (T2DM). The haemodynamic mechanism underlying these effects involves a decrease in efferent resistance with E+L and an increase in afferent resistance with M+I, according to the results of a randomized controlled trial presented at the American Society of Nephrology (ASN) Kidney Week 2019.

Obinutuzumab may be a safe and effective way to control proliferative lupus nephritis, according to the results of the NOBILITY trial, presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).

Azathioprine (AZA) shows similar safety and efficacy as mycophenolate mofetil (MMF) in preventing chronic kidney rejection in kidney transplant recipients who received low-dose cyclosporine A (CsA) and no steroids, according to the ATHENA* study presented at ASN 2019, thus debunking the belief that MMF is better than AZA.

Roxadustat improves haemoglobin levels vs placebo and epoetin alfa, with similar safety profile, in 8,000 patients with chronic kidney disease (CKD)-related anaemia on- and off-dialysis, according to a pooled efficacy and CV safety analyses of roxadustat, spanning over 13,000 patient exposure years.

Treatment with sodium zirconium cyclosilicate in end-stage renal disease (ESRD) patients undergoing haemodialysis (HD) improves potassium balance and lessens the frequency of severe hyperkalaemia episodes, according to a posthoc analysis of the phase IIIB DIALIZE study.

Intensive urate lowering with the combination therapy of verinurad plus febuxostat is successful in lowering the urinary albumin to creatinine ratio (UACR) in patients with type 2 diabetes mellitus (T2DM), albuminuria and hyperuricaemia, according to a study presented at the American Society of Nephrology (ASN) Kidney Week 2019.